Dr. Rüdiger Behr
Head of the Stem Cell Biology Group
German Primate Centre (DPZ), GERMANY

Rüdiger Behr studied Biology at the University of Muenster, Germany. In 1998, he also received his PhD from the University of Muenster working at the Institute of Reproductive Medicine on a project about the endocrine regulation of testicular function in non-human primates. As a postdoc at the University of Pennsylvania at Philadelphia, USA, he used mouse models to study the role of the Foxa transcription factors in testis, kidney and endoderm development. After that, he moved to the Institute of Anatomy, Developmental Biology, at the University of Essen, Germany. There he started working on Rhesus monkey embryonic stem cells and on the role of the transcription factor Krüppel-like factor 4 in the mammalian testis. In 2005, he established the Stem Cell Research Unit at the German Primate Center in Goettingen, Germany, focussing on the common marmoset monkey (Callithrix jacchus) as a NHP model for preclinical and basic stem cell research. 　 More>>

Dr. Sheng Ding
Associate Professor
Department of Chemistry
Scripps Research Institute, USA

The main research focus of the Ding laboratory is to develop and integrate chemical and functional genomic tools to study stem cell biology and regeneration. Over the past few years, they have constructed large combinatorial chemical libraries (>100,000 small molecules) and arrayed cDNA (>30,000 human and mouse genes) and RNAi (targeting over 16,000 human and mouse genes with more than three designed sequences per gene) libraries. Furthermore they have developed and implemented high throughput cellular screens of these libraries to identify small molecules and genes which can control stem cell fate in various systems (including pluripotent embryonic stem cells, multipotent adult neural stem cells and mesenchymal stem cells, and lineage-restricted somatic cells), as well as modulate specific signaling pathways. Moreover, biochemical and cellular studies, including genome-wide expression analysis using Affymetrix microarrays, affinity chromatography for target identification, and cDNA and/or RNAi complementation screens to map signaling pathway, are being used to characterize the molecular mechanism of these identified small molecules and genes. Those studies may ultimately facilitate the therapeutic application of stem cells and the development of small molecule drugs to stimulate tissue and organ regeneration in vivo.　　More>>

Dr. Joseph M. Erwin
Research Professor of Anthropology,
George Washington University, USA
Adjunct Professor of Biomedical Sciences and Pathobiology,
Virginia-Maryland Regional College of Veterinary Medicine
Virginia Polytechnic Institute and State University, USA

Dr. Erwin has been involved in the care and management of nonhuman primates for about 40 years, including service as a zoological curator, research in laboratories and breeding colonies, and a program of field research in Indonesia. He has published or presented more than 300 papers on a range of topics (see PrimateLit), with most of his recent work on the neurobiology of aging and comparative brain morphology. He has designed patented biocontainment enclosures for primates involved in infectious disease research.

Dr. Dayong Gao
Professor
University of Washington, USA

Prof. Gao's research has been focused on the problems in thermal/fluid science and biomedical engineering with funding supports from NIH, NSF, Whitaker Foundation, American Cancer Society, American Heart Association, DoD, and various Industries or research institutions. He has published over 120 original full manuscripts and obtained 12 US patents in certain research areas.　　More>>

Dr. Barbara C. Hansen
Professor of Internal Medicine and Pediatrics
College of Medicine
University of South Florida, Tampa, USA

Dr. Hansen is the Director of the Center for Preclinical Research, which combines the Obesity, Diabetes and Aging Research Center and the Diabetes Complications Prevention Center of the College of Medicine and Professor of Internal Medicine and Pediatrics at the University of South Florida Tampa. Her research has addressed the physiological, cellular, and molecular defects underlying the development of obesity and diabetes mellitus and their prevention, as well as the long-term prevention of diabetic complications.? Dr. Hansen has developed non human primate models of obesity, the metabolic syndrome, diabetes and diabetic complications, and these models are applied to studies of the underlying mechanisms of these disorders, their natural history, and their mitigation/treatment and prevention by pharmaceutical and non pharmaceutical approaches.? Dr. Hansen has been a leader in studies of obesity in non human primates, and has established a large colony of spontaneously obese rhesus monkeys that are used to study the efficacy of new agents, and to establish their potential for translation to patients.

Dr. Gil Hecht
Veterinary Resources
Weizmann Institute of Science, ISRAEL

Dr. Gil Hecht is a veterinarian and IACUC member at the Weizmann institute of science in Israel.  He received a B.Sc. degree in Biology from The Tel-Aviv University and his Ph.D. in transplantation immunology from the Weizmann institute of science.  Dr. Hecht has studied veterinary at the University of Utrecht The Netherlands and he has been active in the area of primate veterinary during the last 7 years. His current research involves study of beta cell regeneration in type-2 diabetes. 　More>>

Dr. Rongqiao He
PI / Deputy Director
Institute of Biophysics Chinese Academy of Sciences, CHINA

More>>

Dr.Xintian HU
Professor
Kunming Biomed International, Ltd., CHINA

Expertise in CNS non-human primates model developing and treatment study. In the past two years，Prof. Hu has direct the development of the nonhuman primates models of Parkinson’s disease (PD), depression and Alzheimer’s disease(AD).

Dr. Tae-Won Kim
Director of Tox, Preclinical Development
Isis Pharmaceuticals, Inc.,USA

Dr. Tae-Won Kim is currently, Director of Toxicology, Isis Pharmaceuticals, Inc. His responsibilities include serving as a representative on several drug development project teams. Design, implementation, interpretation, and reporting of GLP toxicology and pharmacokinetic studies necessary to support IND and NDA application. These studies covered all areas of toxicology testing including general (acute to chronic), genetic, reproductive/fertility, and toxicokinetic assessment. Serve as study monitor and contact to outside contract laboratories. Writing of integrated summaries to describe drug safety profile for IND submission, and other correspondence with FDA.
Dr. Tae-Won Kim joined Isis in 2001 where he served as Group Leader for Department of Pharmacology and Toxicology at SUGEN, Inc. from 1997 - 2001. From 1996 - 1997 he was post-doctoral fellow at University of California, San Francisco. His postgraduate training included research in the areas of oral carcinogenesis. He received his PhD in the Department of Environmental and Molecular Toxicology from North Carolina State University at Raleigh.

Dr. Baoming Li
Professor / Vice-chancellor
Nanchang University, CHINA

More>>

Dr. Ning Li
Academician / Professor
Division of Agriculture
Chinese Academy of Engineering, CHINA
China Agriculture University, CHINA

More>>

Dr. Xiao-Jiang Li, M.D.
Distinguished Professor of Human Genetics
Department of Human Genetics
Emory University School of Medicine, USA

The main interest of the Li Lab is to understand the molecular mechanisms of inherited neurodegeneration caused by a CAG repeat expansion in the disease genes. Currently, they focus on Huntington's disease (HD), an autosomal dominant genetic disease that is characterized by massive neuronal loss in selective brain regions and affects about 5/100,000 people in North America. The HD protein, huntingtin, forms aggregates in neurons, abnormally interacts with other proteins, and eventually kills neurons. 　More>>

Dr. Jeremy J. Mao
Director of Tissue Engineering and Regenerative Medicine Laboratory
Columbia University, USA

Dr. Mao has published over 300 scientific papers, book chapters, conference proceedings and other articles in the areas of tissue engineering, stem cells and regenerative medicine. He also serves on the editorial boards of several scientific journals, including Tissue Engineering and the Journal of Biomedical Material Research and has served on the editorial boards of Stem Cells and Development, Medical Engineering and Physics and Frontiers of Bioscience. Dr. Mao holds numerous patents in the areas of stem cells, tissue engineering and regenerative medicine and is a standing member of the Musculoskeletal Tissue Engineering Study Section of the NIH. In addition to serving as a review panelist for the NIH, Dr. Mao’s scientific expertise has also been sought on a regular basis by NSF and the US Army, as well as many other significant grant-review panels in over 18 countries. 　More>>

Dr. Srinivas Rao, D.V.M., M.B.A., Diplomate, ACVP
Animal Program Director
Chief, Laboratory Animal Medicine
Vaccine Research Center, NIAID, USA

Dr. Rao is a senior scientist and his laboratories' research focuses on developing animal models for various infectious diseases including HIV/SIV, influenza viruses (pandemic H1N1, avian H5N1), and Chikungunya. These animal models include mice, chickens, ferrets, horses, pigs, and nonhuman primates. He currently holds three patents, and his most recent publications feature the development of a virus-like particle vaccine for Chikungunya, the investigation of a potential universal influenza vaccine, and studies in macaque models for primary infection of HIV vaccine trial participants, among others. More>>

Dr. Jianxing Song
Associate Professor
Department of Biochemistry, and
Department of Biological Sciences
National University of Singapore，SINGAPORE

By an integrated utilization of molecular biology, activity assay and various biophysical methods including NMR spectroscopy and crystallography, my laboratory has been mainly focused on delineating signaling mechanisms and further to design/discover small molecules and peptides to block Nogo-NgR and Eph-ephrin interactions, with an ultimate goal to develop drugs to enhance the human CNS regeneration. Additionally, we are also interested in understanding the molecular mechanisms and developing therapeutic approaches for protein aggregation-caused human neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). 　More>>

Dr. Yufang Shi
PI / Director
Institute of Health Sciences
Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, CHINA

Dr. Shi was one of the major researchers in establishing the concept of activation-induced cell death (AICD), a term that is commonly cited in today’s immunology field. He also found the critical role of c-myc in the regulation of T cell apoptosis. His early investigation provided the foundation of using rapamycin as an adjuvant for chemotherapy, which lead to clinical trials in various centers. The research team of Dr. Shi first showed that OPN is a critical molecule in stress-induced corticosteroid production and immunosuppression. Moreover, he proved that CD4+ T cells are responsible for asthma development. In recent studies, his research team investigated the mechanism of bone marrow derive mesenchymal stem cells in the regulation of immunosuppression. Now, he and his team are working on the following aspects: (1) molecular mechanisms of activation-induced cell death in T cell subpopulations; (2) understanding how immunosuppression is mediated mesenchymal stem cells; (3) tumor stroma and tumor immunology. 　 More>>

Dr. Robert Teepe
Head of the Research Coordination
German Primate Centre (DPZ), GERMANY

Dr. Robert Teepe has been head of the unit Research Coordination at the German Primate Center (DPZ) for the last seven years. He was responsible for the administrative issues of the first EUPRIM-Net proposal and tightly involved in the second EUPRIM-Net proposal. In addition he has science management responsibilities. Previously he worked at the University of Goettingen as a researcher.　More>>

Dr. John L. VandeBerg
Director, Southwest National Primate Research Center (SNPRC), USA
Chief Scientific Officer, Southwest Foundation for Biomedical Research (SFBR), USA

Dr. Vandeberg's research interests are focused on geneticphenomena that affect physiological characteristics of humans and othermammals, especially characteristics that predispose to specific diseases. He iscurrently conducting research on genetic and dietary factors that determinecharacteristics of lipoproteins and arterial endothelial cells in relation torisk of coronary heart disease, and the genetic basis of susceptibility toChagas disease. He also directs projects on drug treatment of Chagas disease inthe baboon model and on TB vaccine development in the rhesus monkey model. Dr.VandeBerg has served as a member of the Commission on Life Sciences, NationalAcademy of Sciences; and as Chair of the Institute for Laboratory AnimalResearch Council, National Academy of Sciences. He is an Honorary Diplomate ofthe American College of Laboratory Animal Medicine, a Fellow of the AmericanAssociation for the Advancement of Science, and a National Associate of theNational Academies. 　 More>>

Dr. Mark D. Wallker,D.V.M
VP of Toxicology, Pathology and Laboratory Animal Medicine
Chengdu Frontier BioScience Co. Ltd

Mark Walker graduated with a D.V.M from Texas A&M University in 1985. He completed a postdoctoral residency in Comparative Pathobiology and Primate Medicine/Surgery from Bowman Grey School of Medicine prior to joining Hazleton Laboratories in Vienna, Virginia, in 1990. During his 12 year tenure at Hazleton, which ultimately became Covance Laboratories, he developed a multi-species IV infusion program, expanded specialty toxicology, and functioned as a Principal Scientist and Study Director for the company. As a Scientific Manager, he mentored new Scientists and developed new training and development programs. After leaving Covance, Mark joined Sierra Biomedical in Reno, Nevada, a primate-only toxicology laboratory, to further enhance their expertise and capabilities as a premier NHP CRO. During this 9 year tenure, Mark contributed to the rapid growth and development of the Site and it's expanding areas of safety assessment expertise, to include IV infusion, the design, construction and implementation of a new state-of-the-art multispecies facility, and development of a host of Toxicologist training and development programs. His responsibilities also included the expansion and modernization of Laboratory Sciences, a multidisciplinary group of laboratories dedicated to the support of toxicological research. He has spent his more than 20-year career focusing on and developming training and development programs for toxicologists in the CRO industry, as evidenced by his active involvement in the American College of Toxicology and related forums for professional development. Mark has recently joined Frontier BioSciences, Inc. As a V.P. of Toxicology, Pathology, and Laboratory Animal Medicine, Mark brings his wealth of knowledge and experience to help expand and develop the expertise of a recognized and premier research provider in China, and contribute to the modernization of a rapidly emerging market for drug safety and development.

Dr. Tony Wang
Chief Technology Officer
Kunming Biomed International, Ltd., CHINA

Dr. Jia-Hui Paul Xie
Shanghai Keytag Bioscience co., CHINA

Dr. Shieh came to China to establish KeyTag Bioscience together with Mr. Kao in 2007. Since 1985, Dr. Shieh served as the principal staff scientist at Beckman, R & D manager for the Sigma chromatographic division and the director of research and application departments for ThermoFisher. Hi s research focus n the fields of capillary electrophoresis, chromatography and mass spectrometry. As the prime inventor, Dr. Shieh has plenty of experience in proteomics and he has nine innovation patents, developed more than forty new products and published over 30 articles for the companies he worked for. Dr. Shieh received his Ph.D. in organic chemistry from the North Texas State University.

Dr. Lei Xiao
PI, Shanghai Institute of Biochemistry and Cell Biology
Director, Cell Bank/Stem Cell Bank, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, CHINA

More>>

Dr. Kang Zhang
Director, UCSD Institute for Genomic Medicine, USA
Professor of Ophthalmology & Human Genetics
Shiley Eye Center, UC San Diego, USA



Dr. Zhang's research focuses on the use of molecular genetic techniques to identify genes that predispose patients to retinal diseases and developing drug therapies to prevent these diseases.　　More>>

Dr. Kevin Zhang,
Vice President of Pharmacology
PharmaLegacy Laboritories Co.Ltd.,USA

Formerly held several Director and Associate Director-level positions in the areas of Drug Discovery, Pharmacology, GeneTrove (drug targets), and Pre-clinical Development in Isis Pharmaceticals. An innovator in the field of drug technologies, with more than 50 patents issued or filed.

Dr. Qi Zhou
PI / Director
Division of Reproductive Engineering
Institute of Zoology, Chinese Academy of Sciences, CHINA

Qi Zhou received a PhD in Physiology & Embryology from Northeast Agriculture University, China, 1996 (Thesis: Nuclear transfer and serial nuclear transfer research in rabbit). In 1997-1999 he held a postdoctoral and Associate Professor positition in the Institute of Developmental Biology, Chinese Academay of Sciences (CAS), and in 1999-2002 he was a postdoc and Project leader within the group of Prof. J.P. Renard (Developmental Biology and Reproduction, INRA, Jouy-en-Josas, France). In 2001 he was offered a 100 talent position in the Institute of Zoology, CAS, where he is currently Professor of Developmental Biology, Vice Director of State Key Lab of Reproductive Biology. His research focuses on the mechanisms of differentiation and de-differentiation, particularly, cellular plasticity and totipotency of the stem cells, and the reprogramming mechanisms of the somatic cells. He also focuses on the translation from fundamental researches towards medicine and technology applications to finally promote the development of regenerative medicine.　　More>>

Updated 21st July, 2010